Zelluna ASA
Research Zelluna ASA (ZLNA) on Bullrun: market cap NOK 484.68M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerZLNA
- ExchangeOL
- CountryNorway
- SectorHealthcare
- IndustryBiotechnology
- CurrencyNOK
- Market capNOK 484.68M
- Financial periodQ1 2026
- Net income-NOK 20.37M
- Free cash flow-NOK 28.59M
Valuation Snapshot
latest market cap is NOK 484.68M.
About Zelluna ASA
Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid tumors.
Frequently asked questions
What is Zelluna ASA's market cap?
Zelluna ASA's market capitalization is NOK 484.68M.
What does Zelluna ASA do?
Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma;